Soligenix Shares Gain On HyBrytes Data From Blood Cancer Study
Soligenix Inc (NASDAQ: SNGX) announced the results of its Phase 3 FLASH study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL) had been published in the Journal of the American Medical Association (JAMA) Dermatology.
"The peer-reviewed publication of these data in JAMA Dermatology is a testament and further validation to the importance of the findings for the scientific and CTCL disease communities," stated Ellen Kim, the Lead Principal Investigator for Phase 3 FLASH study.
Also Read: Soligenix's COVID-19 Vaccine Candidate As Booster Neutralizes Delta, Omicron Variants.
The published findings demonstrate that HyBryte statistically significantly reduced lesion size, with the treatment response further improving over successive 6-week treatment cycles.
After the first 6-week treatment window, 16% of patients responded. This response rate continued to increase significantly to 49% through 18 weeks of treatment versus patients with 6-week hypericin or placebo.
Throughout the study, HyBryte was safe and well-tolerated. HyBryte was observed to perform similarly against both patch and thicker plaque lesions characteristic of CTCL.
Price Action: SNGX shares are up 10.63% at $0.80 during the market session on the last check Wednesday.
See more from Benzinga
AIM ImmunoTech Posts Additional Patient Data From Pancreatic Cancer Study
AbbVie, iSTAR Medical Inks Strategic Alliance For Glaucoma Treatment
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.